Our most advanced development programme is a Flavivirus vaccine candidate primarily against Dengue Fever (DV1-DV4), which may also deliver responses against other Flaviviruses such as the Zika and Yellow Fever viruses.
This programme has successfully completed preclinical testing. Phase I and subsequent clinical trials are planned to start in Switzerland, Singapore and Brazil.
We also have programmes in development for a universal Influenza (flu) vaccine, a universal Filovirus vaccine (to target viruses including Ebola and Marburg), a Yellow Fever Booster vaccine, and a Chikungunya virus vaccine.
We are also working on vaccines for several intracellular bacterial infections, such as Francisella tularensis, currently categorized as a Tier 1 biothreat priority by the US government.
We have partnered with the IMCB of Singapore to develop a vaccine for the emerging threat of Hand, Foot and Mouth (HFM) disease.
